People with type 1 diabetes are just as likely to use substances as the rest of the population, so they need to be aware of ...

Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a ...

The American Muslim Heritage Celebration took place at the Institute for Contemporary Art at Virginia Commonwealth University ...

Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical ...

Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes ...

Emily Waldon talks about minor league baseball players Bryce Rainer's prospects and Bennett Lee among other things. (July 19, ...

Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 23, 2026 (GLOBE ...

Under the terms of MacroGenics’ agreement with Sanofi, the recent FDA approval triggered a $24.5 million regulatory milestone payable to MacroGenics. The Company remains eligible to receive up to $305 ...

Brazil patent complements U.S. patent portfolio for NCEL-101, strengthening global position in the type 1 diabetes market. ZURICH, July 15, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. ( ...

The NHS begins offering teplizumab, the first drug shown to delay type 1 diabetes and postpone insulin by nearly three years.

Spero Therapeutics gets a Buy on the immunology pivot, FDA-approved Utebzi, and $105M royalty deal funding SP001. Learn more ...

The appointment follows NewcelX's recently announced successful FDA Type B Pre-IND meeting for NCEL-101, providing a clear regulatory pathway toward clinical trials ...